The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -45,851 |
| Depreciation | 364 |
| Stock-based compensation expense | 5,693 |
| Amortization of right-of-use assets | 540 |
| Accretion of discounts on short-term investments, net | 848 |
| Accounts receivable and unbilled receivable | -591 |
| Prepaid expenses and other current assets | -557 |
| Other assets | 480 |
| Accounts payable and accrued liabilities | 2,202 |
| Operating lease liabilities | -691 |
| Net cash used in operating activities | -37,923 |
| Capital expenditures | 44 |
| Maturities of short-term investments | 71,111 |
| Purchases of short-term investments | 71,860 |
| Sales of short-term investments | 2,135 |
| Net cash provided by investing activities | 1,342 |
| Proceeds from sales of common stock, net of expenses of 0 and 3,286, respectively | 0 |
| Proceeds from exercise of warrants, net of expense of 169 and 0, respectively | 2,088 |
| Proceeds from exercise of options | 493 |
| Net cash provided by financing activities | 2,581 |
| Net change in cash and cash equivalents | -34,000 |
| Cash and cash equivalents - beginning of year | 51,470 |
| Cash and cash equivalents - end of year | 17,470 |
Cardiff Oncology, Inc. (CRDF)
Cardiff Oncology, Inc. (CRDF)